Conrad: the R&D is necessary right now to get the 2 major trials done.
1. TRIPP FX: first RCT of Oncosil combined with Folfirinox which is the standard of care for ca pancreas and
2. PANCOSIL: study of percutaneous delivered Oncosil
These are both underway and maybe a third recruited each. So there's some more R&D spend to come for this FY.
It would be great if Oncosil had more publicly funded trials but alas they don;t. The German trial, if it gets funded, will the first major publicly funded trial.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-12
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.010(1.05%) |
Mkt cap ! $13.65M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.03 | 96.0¢ | $12.69K | 13.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1185 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 7827 | 1 |
View Market Depth
| Last trade - 10.30am 18/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |